Fenofibrate Dosing and Monitoring in Hyperlipidemia with Renal Impairment

Dosing Considerations

For patients with normal renal function (eGFR ≥60 mL/min/1.73m²), the American College of Cardiology recommends starting fenofibrate at 160 mg once daily with meals 1, 2
For moderate renal impairment (eGFR 30-59 mL/min/1.73m²), the initial and maximum dose of fenofibrate is 54 mg once daily 1, 2
Fenofibrate is absolutely contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or those on dialysis 1, 2

The American Heart Association recommends obtaining baseline serum creatinine and calculating eGFR before initiating fenofibrate therapy 1, 3
Baseline hepatic transaminases (ALT, AST) and total bilirubin should be checked before starting fenofibrate 1, 3
Renal function (creatinine and eGFR) should be monitored within 3 months of initiation and every 6 months thereafter 1, 2, 3

The American College of Cardiology warns that gemfibrozil plus any statin is absolutely contraindicated due to markedly increased rhabdomyolysis risk 1
Fenofibrate may be combined with statins only if using low- or moderate-intensity statins, and only if benefits clearly outweigh risks 1, 3
Pravastatin or fluvastatin are safer statin options when combination therapy is necessary 3
The 2013 ACC/AHA guidelines found that fenofibrate added to simvastatin did not reduce cardiovascular events in most patients with diabetes 4, 5

When fenofibrate is contraindicated due to severe renal impairment, consider gemfibrozil at a reduced dose of 600 mg daily 2
Prioritize therapeutic lifestyle modifications 1
Consider omega-3 fatty acids as an alternative for severe hypertriglyceridemia 1
Statins remain superior to fenofibrate for LDL-C lowering with proven cardiovascular outcomes benefit 3